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The Gambia National Cancer Registry (GNCR) is the only popula-
tion-based cancer registry in Africa with national coverage and the
only one covering a substantial rural population. The registry was
established as part of The Gambia Hepatitis Intervention Study
(GHIS). GHIS was designed as a randomized control trial, with
the main aim being to evaluate the effect of hepatitis B vaccination
in infancy on subsequent risk of primary liver cancer (The Gambia
Hepatitis Study Group, 1987). The GNCR was established to
monitor the occurrence of hepatitis B-related liver disease, mainly
primary liver cell carcinoma and cirrhosis of the liver, among the
GHIS cohort. The registry provides a unique opportunity to
describe the pattern of cancer occurrence and outcome in a
predominantly rural population in sub-Saharan Africa. In this
paper, we describe the incident cases of cancer recorded in the
registry in the 10-year period 1988–1997. 
METHODS AND MATERIALS 
The Gambia is a small country in West Africa (11 300 km2) occu-
pying a strip of land on both banks of the river Gambia (Figure 1).
In 1999, the population was estimated to be 1.34 million. It is
divided into 7 administrative districts (5 divisions and 2 munici-
palities), and more than 75% of the population are rural, engaged
in peasant farming and stock rearing. Primary health care is deliv-
ered through village health posts, dispensaries and minor health
centres. Qualified medical doctors at the major health centres and
private ‘non-profit’ institutions provide secondary care. There are
several private clinics, also, mainly in and around the capital city
that deliver general medical care. There are 3 hospitals providing
facilities for tertiary and/or specialist care in The Gambia, viz,
Royal Victoria Hospital (RVH) in the capital city of Banjul,
Bansang Hospital in the centre of the country and the Medical
Research Council Laboratories of the United Kingdom (MRC),
where the GNCR is located (see Figure 1). The RVH and Bansang
hospitals are semi-autonomous government-owned institutions
with services in surgery, dentistry, paediatrics, obstetrics & gynae-
cology, ophthalmology, pathology, radiology (X-ray only) and
general medicine. 
As part of efforts to improve diagnosis of cancer in the country
for the final evaluation of the GHIS project, the International
Agency for Research on Cancer (IARC) has assisted in the estab-
lishment of an in-country histopathology service. This service is at
its infancy, located at the country’s only histopathology laboratory
based at the RVH. 
Notification of cancer is voluntary in The Gambia. Doctors both
in the public and private sector willing to collaborate are supplied
with notification forms designed by the registry. In addition, data
are collected actively by trained field staff from all health institu-
tions that provide secondary or tertiary care. The sources of data
include laboratory reports (mostly histopathology, haematology
and biochemistry), patient case notes, ward admission and
discharge, nursing report books, medical records ledgers and
theatre record books. 
Registration of death is incomplete in Gambia. A death certifi-
cate is only needed in order to obtain a permit for burial within the
capital city, Banjul (with only 6% of the population), or for legal
purposes. Copies of certificates mentioning cancer are obtained
from the registration office. ‘Death Certificate Only’ cases are
those for which no diagnostic information could be found from
any other source. 
Personal interviews with patients are also carried out by the
trained field staff, so as to estimate age and determine usual place
of residence and nationality. Accurate information on age, resi-
dence and nationality are sometimes difficult to obtain since most
Gambians do not know their exact date of birth, and there is
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considerable migration across national or regional borders often in
search of better health care. The Gambia’s immigration service has
issued national identity cards (ID) to all adult citizens (18 and
above), the possession of which is mandatory by law. The ID
contains information on age and usual place of residence. If a
patient is not in possession of a valid ID card, the person is eligible
for inclusion into the cancer register only if he or she has resided
for 3 or more years in the country before first presentation of
symptoms. This criterion effectively excludes non-residents who
came to seek treatment in The Gambia. 
The Registry is computerized and uses the CANREG-3 soft-
ware developed by the International Agency for Research on
Cancer (Cooke, 1998) which is used to search for duplicate regis-
trations. The variables recorded for each patient include personal
and demographic data, the site and histology of the tumour, and
the source of information and basis of diagnosis. Tumour site and
morphology are coded according to the ICD-O (second revision)
(Percy et al, 1990). 
The population at risk was derived from the national censuses of
1983 and 1993. Figure 2 shows the estimate for 1992 (assuming a
constant growth rate between 1983 and 1993), the mid-point of the
10-year period considered here which was used to calculate inci-
dence rates. Age standardization was carried out by the direct
method using the world ‘standard’ population (Doll et al, 1966).
Because of the large number of cases of unknown age (25% of the
total), ASRS were calculated on the assumption that the age distri-
bution of ‘not known’ cases was the same for each site as that of
the known cases (Smith, 1992). 
RESULTS 
Over the 10-year period (1988–1997), a total of 2957 malignant
tumours were registered among residents of The Gambia. Over
60% of the cases were detected at the RVH and MRC. Overall
21% of the malignancies were verified through diagnostic
pathology. Table 2 shows the percentage of histologically
confirmed registrations for selected cancer sites. This ranges from
more than 70% for superficial cancers for example skin
melanomas or Kaposi’s sarcoma, to 4% for deep sited tumours,
notably liver cancers. Serum alpha-fetoprotein, and ultrasound
examination were employed to confirm the clinical diagnosis of
75% of liver cancers. Less than 2% of cases were initially detected
from death certificates without the availability of further informa-
tion from other records to confirm the diagnosis. 
Tables 1a and 1b show the numbers of cases by age group,
together with the all age relative frequencies (%) and crude 
and age-standardized rate (ASR) for males and females 
respectively. 
Among males, liver cancer was most frequent, comprising 58%
of cases (ASR 35.7) followed by non-Hodgkin lymphoma 5.4%
(ASR 2.4), lung cancer 4.0%, (ASR 2.8) and prostate cancer 3.3%
(ASR 2.5). The most frequent sites of cancer in females by rank
order were cervix uteri 34.0% (ASR 18.9), liver 19.4% (ASR
11.2), breast 9.2% (ASR +5.5) and ovary 3.2% (ASR 1.6). The
overall age standardized incidence rates were 61.0 and 55.7 per
100 000 for males and females respectively. 
A total of 149 lymphomas were registered during the period.
These include 17 cases of Hodgkin’s disease and 132 non-
Hodgkin lymphomas. Overall, more than 50% of the lymphomas
had histological confirmation of the diagnosis, the rest were 
registered on clinical grounds. 25 cases of Burkitt’s lymphoma
were included in the register. With the exception of 1 case of
unknown age and another in age group 25–34, all were in the age
range of 0–14 years and 30% had histological verification of 
diagnosis. 
28 cases of Kaposi’s sarcoma were registered. There were 6
cases diagnosed by lymph node biopsy and one with unknown
primary site. Apart from these, all were localized in the lower limb
or were of the generalized ‘epidemic’ disseminated type. 
Age-specific incidence rates for the leading cancer sites in
males and females are shown in Figures 3 and 4, respectively.
Liver cancer begins to increase at younger ages in males than in
females and unlike males, incidence rates in females reach a
maximum after age 40 years. In men, prostate cancer increases
sharply after age 50 and is more common in the oldest age 
groups. The incidence of cervix cancer rises rapidly in young
women, to reach a maximum at age 40. Breast cancer increases
less dramatically with age, and becomes more common than
cervix cancer after age 40 before declining in the oldest age
groups. 
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DISCUSSION 
There is particular concern with the accuracy of the data when
examining the results from cancer registries in the economically
underdeveloped countries of Africa. The weak health-care infra-
structure and paucity of diagnostic services mean that diagnosis
and treatment of cancer, a disease affecting a relatively small
number of people and with a very uncertain outcome, has a low
priority. The Gambia National Cancer Registry is the only African
registry serving an entire national population, the great majority of
whom are rural peasant farmers. Nothing is known concerning
their behaviour when faced with diseases such as cancer, whether
they will present for diagnosis and treatment at local health centres
and, having done so, whether they will proceed to tertiary health
centres for diagnosis and treatment. Without special studies, the
only bases for evaluating completeness of registration are by
making comparisons with other similar populations, by studying
the stability of incidence rates over time, and by looking at the
proportion of cases histologically verified (Parkin et al, 1994). 
With respect to stability of rates, there was an increase in the
annual numbers of registrations, which had been about 275 per
year (and increasing gradually) in 1988–1996, to 480 per year in
1997. This coincided with a modification in registration methods
(the permanent out-posting of registry personnel to the major
hospitals) and it does suggest that there was some under-registration
in the earlier part of the period considered here. As noted in the
Methods section, the death certificate registrations are of little use
in evaluating completeness, since death certificates are completed
only in hospitals (and so do not constitute an independent source
of case finding). The very low proportion of cases histologically
verified (overall, and for all sites) at least indicates that the registry
is not over-dependent on laboratory diagnoses, and that clinical
case finding is successful. 
Comparisons with other data from West and East Africa (and
the USA) are shown in Table 3. Some caution is needed in inter-
pretation, since all of the other African series are from urban
centres, with concentrated diagnostic and treatment facilities
easily (physically) accessible to the population who are, in any
case, probably better informed and more likely to seek medical
attention than their rural cousins. Having noted this, it is difficult
to know whether the low incidence rates for many sites in The
Gambia represent under-diagnosis, under-ascertainment, low inci-
dence rates in a rural population, or genuine geographic variation
in risk. 
In women, the relative low incidence in cervix cancer
(compared to other African registries) suggests that cases are not
being diagnosed. There is no reason to suppose that rates of this
cancer would be low in rural women (the reverse is the case in
India (Jayant et al, 1997; Rajkumar et al, 2000)). Since this is a
relatively simple clinical diagnosis (and only 22% of cases that
were registered had histology), this probably means that many
women with cervical cancer do not present to medical attention.
Likewise, the very low incidence of prostate cancer in men is quite
likely the effect of under-diagnosis rather than any genuine
geographic variation in risk. 
Even though the recorded incidence of cervix cancer (age stan-
dardized rate 18.9 per 100 000) is probably an underestimate, it
remains the most common cancer of women. Incidence in young
women aged 25–34 (11.6 per 100 000) is relatively high (and,
since one quarter of cases have no age recorded, this too is an
underestimate). HPV has been unequivocally demonstrated as the
major risk factor for cervix cancer (Herrero and Muñoz, 1999),
acquisition of the virus being related to multiple sexual partners
and early intercourse. The risk is augmented by high parity
(Brinton et al, 1989) and possibly by other genital infections (de
Sanjose, 1994). Thus, the high incidence rates in West Africa are
consistent with early age at marriage, high parity, polygamy and
high rates of STD (Meda et al, 1997) in the region. There are no
programmes of cervical cancer prevention in the country. 
The incidence of liver cancer is probably the most accurately
measured. Because of the setting of the GHIS, special attention is
paid to identifying all possible cases, and an effort has been made
to ensure that diagnostic ultrasound (US) is available in all 3
referral hospitals, and a laboratory service for alpha-fetoprotein
(AFP) estimation available to all collaborating hospitals and health
centres on simple request. In our data more than 70% of cases have
been diagnosed by ultrasound and/or AFP. AFP has been shown to
have a sensitivity and specificity for hepatocellular carcinoma of
90% if a cut-off of 400 ng ml–1 is used (Kew, 1975). In the
Sahelian region, this has been shown to be improved by the 
addition of ultrasound examination (Tortey et al, 1985). Even so,
there has been some fluctuation in the annual numbers of 
cases registered – including deficits in 1990 and 1994 when the
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Figure 4ultrasound service was out of action – so that the rates even as
recorded are something of an underestimate. Nevertheless, they
are quite comparable to the contemporary data from Guinea and 
Mali (Table 3), and from Dakar, Senegal, in the early 1970s
(Waterhouse et al, 1982). The rapid increase in incidence with age
in young males is typical of Africa (Muñoz et al, 1982). 
Epidemiological studies have clearly established chronic
carriage of hepatitis B virus (HBV) as a dominant factor in the
aetiology of HCC (IARC, 1994). Exposure to aflatoxin is also an
important risk factor, particularly in association with chronic
carriage of hepatitis B virus (Qian et al, 1994). A high prevalence
of HBV infection and its chronic carriage (Whittle et al, 1990) as
well as dietary exposure to aflatoxin (Wild et al, 1990) were
reported from The Gambia. A case–control study of liver cancer in
The Gambia has clearly shown that hepatitis B is the dominant risk
factor (Ryder et al, 1992). There is evidence of inter-tribal varia-
tion in aflatoxin levels and carriage of hepatitis B surface antigen
(HBsAg) in Gambian children, and an association between afla-
toxin and chronic carriage of HBsAg has also been observed
(Allen et al, 1992). Aflatoxin-albumin adducts levels were found
to be higher in the children of the Wollof and Fula tribes (Allen 
et al, 1992; Wild et al, 1993) than in the other tribal groups. Whether
this phenomenon is reflected in a significantly higher rate of liver
cancer in adults has not yet been studied. The relatively high inci-
dence of liver cancer, and the presence of a well functioning
expanded programme of immunization (EPI) were factors which
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Table 2 Percentage of histologically verified (HV) cancer cases 
Site Number HV% 
Liver 1169 4 
Cervix 481 22 
Oral cavity and pharynx 54 46 
Oesophagus 35 28 
Stomach 92 21 
Colon and rectum 74 27 
Pancreas 28 23 
Bronchus and lung 72 11 
Skin melanoma 16 75 
Skin, other 45 63 
Kaposi’s sarcoma 28 76 
Breast 133 53 
Prostate 51 25 
Bladder 36 19 
Lymphoma 149 56 
Leukaemia 26 59 
Others 468 53 
All sites 2957 21 
Table 3 Age-Standardized incidence rates: The Gambia, selected African and USA registries 
a.Males
West Africa East Africa USA 
Site The Gambia Mali Bamako1 Guinea Conakry2 Cote d’Ivoire Abidjan3 Zimbabwe Harare4 Uganda Kampala5 US (SEER) Black1
1988–1997 1988–1992 1992–1995 1995–1997 1993–1995 1995–1997 1988–1992
Oesophagus 1.1 1.7 0.6 0.7 19.6 13.0 13.8 
Stomach 2.3 19.6 6.1 3.3 12.3 7.6 14.5 
Colon & Rectum 1.6 6.0 2.3 2.4 6.8 6.8 46.4 
Liver 35.7 51.1 32.8 10.0 30.2 5.9 6.5 
Bronchus & Lung 2.8 5.3 4.9 6.2 14.1 3.2 99.1 
Skin Melanoma 0.3 0.5 1.3 0.7 1.5 1.1 0.7 
Prostate 2.5 5.4 8.1 31.4 26.0 39.2 137.0 
Bladder 1.0 10.6 3.8 2.2 8.9 2.9 11.1 
Eye 0.4 1.2 0.5 0.1 1.4 3.0 0.4 
Non-Hodgkin Lymphoma 2.4 2.6 2.3 3.3 4.5 7.4 12.3 
Leukaemia 0.6 0.9 0.3 1.0 2.1 1.1 9.1 
Kaposi’s Sarcoma 0.6 – 0.1 2.2 47.2 39.3 7.0 
All sites 61.0 129.5 83.0 83.7 212.1 166.6 445.3 
b. Females
Oesophagus 0.3 0.8 0.8 0.2 9.5 14.2 3.9 
Stomach 1.9 10.3 5.7 4.5 11.0 5.6 5.9 
Colon & Rectum 1.5 3.0 1.7 2.5 7.3 7.3 25.3 
Liver 11.2 21.4 12.5 5.6 12.3 6.3 2.0 
Bronchus & Lung 0.4 2.6 0.9 1.2 7.3 3.2 38.5 
Skin Melanoma 0.4 0.9 1.1 1.4 4.4 2.2 0.5 
Breast 5.5 10.2 10.9 21.4 18.6 22.0 79.3 
Cervix uteri 18.9 23.4 46.0 26.8 53.8 44.1 12.0 
Corpus uteri 3.1 0.8 1.1 2.3 4.7 4.0 11.4 
Ovary 1.6 1.0 1.8 4.0 6.1 5.3 8.1 
Eye 0.3 1.0 0.3 0.9 1.9 3.0 0.3 
Thyroid 0.4 1.7 0.6 1.5 3.8 5.6 3.3 
Non-Hodgkin Lymphoma 1.2 0.4 1.3 2.9 3.8 5.7 7.0 
Leukaemia 0.8 2.5 0.5 2.7 3.3 1.9 5.8 
Kaposi’s Sarcoma 0.3 – 0.1 0.6 17.3 22.0 0.2 
All sites 55.7 102 110.5 98.6 210.1 179.7 272.6 
1Parkin et al, 1997. 2Koulibaly et al, 2000. 3Echimane et al, 2000. 4Chokunonga et al, 2000. 5Wabinga et al, 2000. led to the choice of The Gambia for the trial of efficacy of vacci-
nation against hepatitis B (Gambia Hepatitis Study Group, 1987).
Recent data have shown the vaccine to be 84% effective against
infection and over 90% effective against chronic carriage of HBV
(Viviani et al, 1999). A clear effect on incidence of liver cancer
should be evident in this study by 2025. 
Kaposi’s sarcoma remains relatively uncommon, just 18 cases
in males and 10 in females. Only 3 of these cases were in elderly
men (aged 50 or more); the great majority of the remainder are
probably related to HIV. The numbers of cases in young subjects
aged under 50 increased from 3 in the 8 years 1988–1995 to 11 in
1996–1997. The incidence remains low, however, in comparison
to East Africa (Table 3). Prior to the AIDS epidemic, KS was a
relatively rare cancer in West Africa, in comparison with the
endemic areas in the east and centre of the continent (Oettlè,
1962). This may have been a reflection of a difference in preva-
lence of infection with the causative agent human herpes virus 8
(HHV-8) (IARC, 1998), although contemporary seroprevalence of
anti-HHV-8 antibodies in Gambia is high, and quite comparable to
those areas with high incidence of endemic KS (Lennette et al,
1996; Ariyoshi et al, 1998). The AIDS epidemic arrived rather
later in West Africa than in the east and centre of the continent.
The current prevalence of infection in The Gambia is 1.1% for
HIV-2 and 0.5% for HIV-1 (O’Donovan et al, 2000). It seems that
KS is a more frequent complication of HIV-1 infection than HIV-2
– in their study in The Gambia, Ariyoshi et al (1998) found that
8.2% of HIV-1 positive patients with AIDS had KS, compared
with 0.8% of AIDS coming years, and already mixed infections
with both viruses are reported. 
In contrast to an earlier review of the GNCR data (Bah 
et al, 1990), lung cancer is now among the common male cancers
in The Gambia (second in terms of ASR). This phenomenon 
can be attributed to improved diagnosis, specifically the avail-
ability of a bronchoscope at the MRC during recent times.
Nevertheless, cancers of the lung, colon and rectum, the most
frequent cancers of industrialised countries, remain relatively rare
in The Gambia. 
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